Last 12 months
Inside the activity.
0 purchase rows · 35 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 16 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 17 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2025 Filed May 2, 2025 20:14 UTC |
Romanelli JosephPresident, Human Health Int?l
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013182 · form4.xml · derivative · entry 6 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,262 Underlying: Common Stock · 2,262 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2025 Filed May 2, 2025 20:14 UTC |
Romanelli JosephPresident, Human Health Int?l
|
Tax withholdingCommon Stock | 1,115 | $83.26 | $92,834.90 |
DisclosureSEC source: 0001127602-25-013182 · form4.xml · nonDerivative · entry 4 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,945.545 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2025 Filed May 2, 2025 20:14 UTC |
Romanelli JosephPresident, Human Health Int?l
|
Exercise / conversionCommon Stock | 2,262 | $83.26 | $188,334.12 |
DisclosureSEC source: 0001127602-25-013182 · form4.xml · nonDerivative · entry 3 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,060.545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2025 Filed May 2, 2025 20:18 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Exercise / conversionRestricted Stock Unit · Derivative | 381 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013190 · form4.xml · derivative · entry 6 Smart Dalton E. III · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383 Underlying: Common Stock · 381 shares Expires 2026-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 02, 2025 Filed May 2, 2025 20:18 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Tax withholdingCommon Stock | 131 | $83.26 | $10,907.06 |
DisclosureSEC source: 0001127602-25-013190 · form4.xml · nonDerivative · entry 4 Smart Dalton E. III · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,332.802 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 02, 2025 Filed May 2, 2025 20:18 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Exercise / conversionCommon Stock | 381 | $83.26 | $31,722.06 |
DisclosureSEC source: 0001127602-25-013190 · form4.xml · nonDerivative · entry 3 Smart Dalton E. III · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,463.802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:12 UTC |
Larson Betty DEVP, Chief HR Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 11,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013174 · form4.xml · derivative · entry 3 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,700 Underlying: Common Stock · 11,350 shares Expires 2027-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:12 UTC |
Larson Betty DEVP, Chief HR Officer
|
Tax withholdingCommon Stock | 5,153 | $84.71 | $436,510.63 |
DisclosureSEC source: 0001127602-25-013174 · form4.xml · nonDerivative · entry 2 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,197 Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:12 UTC |
Larson Betty DEVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 11,350 | $84.71 | $961,458.50 |
DisclosureSEC source: 0001127602-25-013174 · form4.xml · nonDerivative · entry 1 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:14 UTC |
Romanelli JosephPresident, Human Health Int?l
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013182 · form4.xml · derivative · entry 5 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,128 Underlying: Common Stock · 2,063 shares Expires 2027-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:14 UTC |
Romanelli JosephPresident, Human Health Int?l
|
Tax withholdingCommon Stock | 1,017 | $84.71 | $86,150.07 |
DisclosureSEC source: 0001127602-25-013182 · form4.xml · nonDerivative · entry 2 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,798.545 Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:14 UTC |
Romanelli JosephPresident, Human Health Int?l
|
Exercise / conversionCommon Stock | 2,063 | $84.71 | $174,756.73 |
DisclosureSEC source: 0001127602-25-013182 · form4.xml · nonDerivative · entry 1 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,815.545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:18 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Exercise / conversionRestricted Stock Unit · Derivative | 464 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013190 · form4.xml · derivative · entry 5 Smart Dalton E. III · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 929 Underlying: Common Stock · 464 shares Expires 2027-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:18 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Tax withholdingCommon Stock | 159 | $84.71 | $13,468.89 |
DisclosureSEC source: 0001127602-25-013190 · form4.xml · nonDerivative · entry 2 Smart Dalton E. III · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,082.802 Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:18 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Exercise / conversionCommon Stock | 464 | $84.71 | $39,305.44 |
DisclosureSEC source: 0001127602-25-013190 · form4.xml · nonDerivative · entry 1 Smart Dalton E. III · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,241.802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2025 Filed May 1, 2025 21:43 UTC |
Romanelli JosephPresident, Human Health Int?l
|
GrantStock Option (Right to Buy) · Derivative | 21,494 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013014 · form4.xml · derivative · entry 4 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,494 Underlying: Common Stock · 21,494 shares Expires 2035-04-28 F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 21:43 UTC |
Romanelli JosephPresident, Human Health Int?l
|
GrantRestricted Stock Unit · Derivative | 9,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013014 · form4.xml · derivative · entry 3 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,444 Underlying: Common Stock · 9,444 shares Expires 2028-04-29 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 21:43 UTC |
Romanelli JosephPresident, Human Health Int?l
|
GrantRestricted Stock Unit · Derivative | 4,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013014 · form4.xml · derivative · entry 2 Romanelli Joseph · CIK 0001938322 · President, Human Health Int?l 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,722 Underlying: Common Stock · 4,722 shares Expires 2028-04-29 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 21:45 UTC |
Guindo ChirfiChief Marketing Officer
|
GrantStock Option (Right to Buy) · Derivative | 26,867 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013018 · form4.xml · derivative · entry 4 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,867 Underlying: Common Stock · 26,867 shares Expires 2035-04-28 F5 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 21:45 UTC |
Guindo ChirfiChief Marketing Officer
|
GrantRestricted Stock Unit · Derivative | 5,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013018 · form4.xml · derivative · entry 3 Guindo Chirfi · CIK 0001722753 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,902 Underlying: Common Stock · 5,902 shares Expires 2028-04-29 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 21:58 UTC |
Larson Betty DEVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 28,479 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013031 · form4.xml · derivative · entry 3 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,479 Underlying: Common Stock · 28,479 shares Expires 2035-04-28 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 21:58 UTC |
Larson Betty DEVP, Chief HR Officer
|
GrantRestricted Stock Unit · Derivative | 6,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013031 · form4.xml · derivative · entry 2 Larson Betty D · CIK 0001617903 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,257 Underlying: Common Stock · 6,257 shares Expires 2028-04-29 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:00 UTC |
Downing Cristal NChief Comm. & Public Afrs Ofcr
|
GrantStock Option (Right to Buy) · Derivative | 13,971 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013034 · form4.xml · derivative · entry 3 Downing Cristal N · CIK 0001879216 · Chief Comm. & Public Afrs Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,971 Underlying: Common Stock · 13,971 shares Expires 2035-04-28 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:00 UTC |
Downing Cristal NChief Comm. & Public Afrs Ofcr
|
GrantRestricted Stock Unit · Derivative | 3,069 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013034 · form4.xml · derivative · entry 2 Downing Cristal N · CIK 0001879216 · Chief Comm. & Public Afrs Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,069 Underlying: Common Stock · 3,069 shares Expires 2028-04-29 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:03 UTC |
Zachary JenniferEVP, General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 40,301 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013037 · form4.xml · derivative · entry 3 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,301 Underlying: Common Stock · 40,301 shares Expires 2035-04-28 F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:03 UTC |
Zachary JenniferEVP, General Counsel
|
GrantRestricted Stock Unit · Derivative | 8,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013037 · form4.xml · derivative · entry 2 Zachary Jennifer · CIK 0001737231 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,854 Underlying: Common Stock · 8,854 shares Expires 2028-04-29 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:04 UTC |
Li Dean YExecutive VP & President, MRL
|
GrantStock Option (Right to Buy) · Derivative | 64,481 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013039 · form4.xml · derivative · entry 3 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,481 Underlying: Common Stock · 64,481 shares Expires 2035-04-28 F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:04 UTC |
Li Dean YExecutive VP & President, MRL
|
GrantRestricted Stock Unit · Derivative | 14,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013039 · form4.xml · derivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,166 Underlying: Common Stock · 14,166 shares Expires 2028-04-29 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:06 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
GrantStock Option (Right to Buy) · Derivative | 18,807 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013043 · form4.xml · derivative · entry 3 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,807 Underlying: Common Stock · 18,807 shares Expires 2035-04-28 F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:06 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
GrantRestricted Stock Unit · Derivative | 4,132 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013043 · form4.xml · derivative · entry 2 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,132 Underlying: Common Stock · 4,132 shares Expires 2028-04-29 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:07 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
GrantStock Option (Right to Buy) · Derivative | 181,623 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013046 · form4.xml · derivative · entry 3 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,623 Underlying: Common Stock · 181,623 shares Expires 2035-04-28 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:07 UTC |
Davis Robert MDirector · Chairman, CEO & President
|
GrantRestricted Stock Unit · Derivative | 39,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013046 · form4.xml · derivative · entry 2 Davis Robert M · CIK 0001363076 · Director · Chairman, CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,901 Underlying: Common Stock · 39,901 shares Expires 2028-04-29 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:10 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
GrantStock Option (Right to Buy) · Derivative | 34,390 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013049 · form4.xml · derivative · entry 4 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,390 Underlying: Common Stock · 34,390 shares Expires 2035-04-28 F5 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:10 UTC |
DeLuca Richard R.EVP&Pres, Merck Animal Heallth
|
GrantRestricted Stock Unit · Derivative | 7,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013049 · form4.xml · derivative · entry 3 DeLuca Richard R. · CIK 0001421339 · EVP&Pres, Merck Animal Heallth 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,555 Underlying: Common Stock · 7,555 shares Expires 2028-04-29 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:12 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
GrantStock Option (Right to Buy) · Derivative | 35,465 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013051 · form4.xml · derivative · entry 6 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,465 Underlying: Common Stock · 35,465 shares Expires 2035-04-28 F7 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:12 UTC |
Chattopadhyay SanatExe V-P & Pres. MMD
|
GrantRestricted Stock Unit · Derivative | 7,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013051 · form4.xml · derivative · entry 5 Chattopadhyay Sanat · CIK 0001670690 · Exe V-P & Pres. MMD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,791 Underlying: Common Stock · 7,791 shares Expires 2028-04-29 F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F6 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:13 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
GrantStock Option (Right to Buy) · Derivative | 18,807 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013053 · form4.xml · derivative · entry 3 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,807 Underlying: Common Stock · 18,807 shares Expires 2035-04-28 F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:13 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
GrantRestricted Stock Unit · Derivative | 4,132 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013053 · form4.xml · derivative · entry 2 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,132 Underlying: Common Stock · 4,132 shares Expires 2028-04-29 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:15 UTC |
Litchfield CarolineEVP & CFO
|
GrantStock Option (Right to Buy) · Derivative | 53,735 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013055 · form4.xml · derivative · entry 3 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,735 Underlying: Common Stock · 53,735 shares Expires 2035-04-28 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:15 UTC |
Litchfield CarolineEVP & CFO
|
GrantRestricted Stock Unit · Derivative | 11,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013055 · form4.xml · derivative · entry 2 Litchfield Caroline · CIK 0001854928 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,805 Underlying: Common Stock · 11,805 shares Expires 2028-04-29 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:19 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
GrantStock Option (Right to Buy) · Derivative | 6,448 | $0.00 Strike: $84.71 | $0.00 |
DisclosureSEC source: 0001127602-25-013057 · form4.xml · derivative · entry 3 Smart Dalton E. III · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,448 Underlying: Common Stock · 6,448 shares Expires 2035-04-28 F4 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:19 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
GrantRestricted Stock Unit · Derivative | 2,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013057 · form4.xml · derivative · entry 2 Smart Dalton E. III · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,833 Underlying: Common Stock · 2,833 shares Expires 2028-04-29 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 4/29/2026, 4/29/2027 and 4/29/2028. Read SEC document |
| April 25, 2025 Filed Apr 29, 2025 20:04 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $58.08 | $0.00 |
DisclosureSEC source: 0001127602-25-012727 · form4.xml · derivative · entry 3 Smart Dalton E. III · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. Read SEC document |
| April 25, 2025 Filed Apr 29, 2025 20:04 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
SaleCommon Stock | 4,262 | $82.76 | $352,723.12 |
DisclosureSEC source: 0001127602-25-012727 · form4.xml · nonDerivative · entry 2 Smart Dalton E. III · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,777.802 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| April 25, 2025 Filed Apr 29, 2025 20:04 UTC |
Smart Dalton E. IIISVP Fin. - Global Controller
|
Exercise / conversionCommon Stock | 5,000 | $58.08 | $290,400.00 |
DisclosureSEC source: 0001127602-25-012727 · form4.xml · nonDerivative · entry 1 Smart Dalton E. III · CIK 0002003375 · SVP Fin. - Global Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,039.802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 13:50 UTC |
Coe Mary EllenDirector
|
GrantPhantom Stock · Derivative | 334.2246 | $89.76 | $30,000.00 |
DisclosureSEC source: 0001127602-25-010918 · form4.xml · derivative · entry 2 Coe Mary Ellen · CIK 0001691304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,567.8829 Underlying: Common Stock · 334.2246 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 13:53 UTC |
GLOCER THOMAS HDirector
|
GrantPhantom Stock · Derivative | 543.115 | $89.76 | $48,750.00 |
DisclosureSEC source: 0001127602-25-010922 · form4.xml · derivative · entry 2 GLOCER THOMAS H · CIK 0001140799 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,578.6409 Underlying: Common Stock · 543.115 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 13:57 UTC |
Seidman Christine EDirector
|
GrantPhantom Stock · Derivative | 90.5192 | $89.76 | $8,125.00 |
DisclosureSEC source: 0001127602-25-010926 · form4.xml · derivative · entry 2 Seidman Christine E · CIK 0001805745 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,377.6146 Underlying: Common Stock · 90.5192 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 21:01 UTC |
Oosthuizen Johannes JacobusPresident, U.S. Market
|
SaleCommon Stock | 8,500 | $84.09 | $714,744.60 |
DisclosureSEC source: 0001127602-25-005928 · form4.xml · nonDerivative · entry 1 Oosthuizen Johannes Jacobus · CIK 0001916310 · President, U.S. Market 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,705.474 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.0700 to $84.1000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
| February 13, 2025 Filed Feb 13, 2025 21:01 UTC |
Williams David MichaelEVP,Chief Info&Digital Officer
|
SaleCommon Stock | 6,000 | $85.34 | $512,056.80 |
DisclosureSEC source: 0001127602-25-004615 · form4.xml · nonDerivative · entry 1 Williams David Michael · CIK 0001820958 · EVP,Chief Info&Digital Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,123.316 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.